A new publication in Acta Materia Medica journal discusses the potential of G protein-coupled receptors (GPCRs) as drug targets for metabolic disorders like obesity. GPCRs interact with various transducers and biased agonism can activate specific therapeutic pathways. The structural techniques like X-ray crystallography have helped understand how biased agonism affects downstream responses. The article emphasizes the importance of identifying GPCR targets for obesity treatment and the role of biased signaling in drug development. Effective treatments for obesity are limited, making the study of GPCRs crucial for addressing this global health threat. The authors highlight validated GPCR targets and promising receptors for obesity treatment.
Source link
Deciphering the role of GPCRs in obesity pathology for drug development
